BioLargo, Inc.
BLGO
$0.13
-$0.01-5.00%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 80.71% | -44.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 80.71% | -44.06% | |||
| Cost of Revenue | 34.36% | -33.11% | |||
| Gross Profit | 257.81% | -65.59% | |||
| SG&A Expenses | -20.51% | -50.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.39% | -44.30% | |||
| Operating Income | 19.84% | 44.33% | |||
| Income Before Tax | 17.79% | 42.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.79% | 42.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -5.89% | 55.42% | |||
| Net Income | 22.59% | 54.42% | |||
| EBIT | 19.84% | 44.33% | |||
| EBITDA | 20.74% | 44.53% | |||
| EPS Basic | 23.40% | 55.24% | |||
| Normalized Basic EPS | 27.27% | 63.93% | |||
| EPS Diluted | 23.40% | 55.24% | |||
| Normalized Diluted EPS | 27.27% | 63.93% | |||
| Average Basic Shares Outstanding | 1.40% | 1.72% | |||
| Average Diluted Shares Outstanding | 1.40% | 1.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||